Latest studies
- Active not recruitingPHASE3
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
This study is looking into a new drug, zipalertinib, for people with a certain type of lung cancer (NSCLC) in its early stages. It compares zipalertinib with standard chemotherapy to a dummy pill (placebo) with standard chemotherapy after surgery.
Lung CancerAdjuvantPost-surgicalEGFRBelgium - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
Carcinoma, Non-Small-Cell LungBelgium - Active not recruitingPHASE1
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
This study is looking at a new medicine called Runimotamab for people with certain advanced HER2-positive cancers. It aims to see if it's safe and how it works, both alone and with other treatments like Trastuzumab.
Solid TumorsBelgium - RecruitingPHASE3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
This study looks at a new medicine, Baxdrostat, combined with an existing one, Dapagliflozin, for people with long-term kidney disease and high blood pressure. It aims to see if this combination can help protect the kidneys and heart better than Dapagliflozin alone.
Chronic Kidney Disease and HypertensionBelgium - RecruitingPHASE1, PHASE2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
This study is testing a new medicine called VTx-002 for people with Motor Neurone Disease (ALS). It aims to see if it's safe and how well people can cope with it. Researchers will also look at how it affects the disease over five years.
Amyotrophic Lateral SclerosisBelgium - RecruitingPHASE3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, riliprubart, against the usual treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It's for adults already receiving IVIg to see if riliprubart works safely and effectively to manage their condition.
Chronic Inflammatory Demyelinating PolyneuropathyBelgium - RecruitingNA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
This study looks at treating hip fractures quickly in older patients who also have heart problems. It compares fast surgery to usual care to see if it reduces deaths within 90 days, and also checks other important health outcomes.
Hip FracturesMyocardial InjuryBelgium - Active not recruitingPHASE3
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
This study is looking at a new way to give medicine for advanced melanoma. We want to see if an injection under the skin works as well as the usual drip into a vein. This might make treatment easier for patients.
MelanomaBelgium - Recruiting
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
This study looks back at people in the UK and other countries who received a treatment called teplizumab for Type 1 diabetes through special early access schemes. It aims to understand how the treatment was used and the characteristics of the patients.
Type 1 DiabetesBelgium - Active not recruitingPHASE3
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
This study looks at a new inhaled medicine, molgramostim, for a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP). We want to see if it helps patients better than a dummy treatment. After 48 weeks, everyone gets the active medicine.
Autoimmune Pulmonary Alveolar ProteinosisBelgium - Active not recruitingPHASE3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard hormone therapy for advanced prostate cancer. It aims to see if the new treatment helps people live longer or keeps their cancer in check for longer, for those who haven't had certain chemotherapy.
Prostatic NeoplasmsBelgium - RecruitingPHASE2, PHASE3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
This study compares two medicines, zanzalintinib and everolimus, for treating advanced neuroendocrine tumours. It aims to see which is more effective for people whose tumours have grown or spread despite previous treatments. This is a crucial step in finding better ways to manage this condition.
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)Belgium - RecruitingPHASE3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
This study looks at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares switching from their current medicine, ocrelizumab, to remibrutinib, versus staying on ocrelizumab, to see if it's safe and works well.
Relapsing Multiple SclerosisBelgium - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
This study is looking at a new medication, sotagliflozin, to see if it can help people with a heart condition called hypertrophic cardiomyopathy (HCM). It aims to find out if the drug improves symptoms and daily activities compared to a dummy pill.
Obstructive Cardiomyopathy, HypertrophicNon-obstructive Hypertrophic CardiomyopathyBelgium - RecruitingNA
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
This study looks at whether a special feature in a Medtronic pacemaker can help lower high blood pressure. It compares having this feature on versus off in people who either need a pacemaker or already have one and also have high blood pressure.
HypertensionHypertension, SystolicHypertension, EssentialBelgium - RecruitingPHASE2, PHASE3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
This study is testing a new medicine, VX-147, for people aged 10-65 with a specific type of kidney disease caused by a gene problem. It will check if the medicine helps, if it's safe, and how the body handles it.
Proteinuric Kidney DiseaseBelgium - RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two medicines, BGB-16673 and pirtobrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when previous treatments haven't worked well enough. It aims to see which medicine is safer and more effective.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaBelgium - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
This study is testing a new medicine, volixibat, for people with Primary Sclerosing Cholangitis (PSC) who experience bothersome itching. It aims to see if the medicine can reduce itching and affect how PSC progresses.
Primary Sclerosing CholangitisBelgium - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesBelgium - Active not recruitingPHASE2
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
This study looks at a medicine called PF-07868489 for people with high blood pressure in their lungs (Pulmonary Arterial Hypertension). It's for those who have already tried this medicine in an earlier study, to see if it's safe and helps them over a longer time.
Pulmonary HypertensionBelgium - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positiveBelgium - RecruitingPHASE2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This study is testing a new medicine, IMVT-1402, for adults with Graves' disease whose thyroid is still overactive despite current treatment. We want to see if it works, is safe, and is well-tolerated. It's a Phase 2 trial. You can find out more if you're interested.
Graves' DiseaseBelgium - Active not recruitingNA
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
This study looks at a treatment called renal denervation (RDN) for high blood pressure. It uses a device called Symplicity Spyral to see how well it works and if it's safe in the long term, especially for people whose blood pressure is hard to control.
HypertensionVascular DiseasesCardiovascular DiseasesChronic Kidney DiseasesBelgium - RecruitingPHASE3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is testing a new medicine, Pasritamig, for men with advanced prostate cancer that has spread and is no longer responding to hormone treatments. We want to see if Pasritamig helps men live longer compared to a dummy medicine, alongside their usual supportive care.
Metastatic Castration-resistant Prostatic NeoplasmsBelgium - RecruitingPHASE3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
This study is looking into whether a medicine called baricitinib can delay Type 1 Diabetes in children and adults who are at a high risk of developing it. It's a key step in preventing the condition.
Diabetes Mellitus, Type 1Belgium - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerBelgium - Available
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
This program offers a new medicine called zidesamtinib to adult patients in the UK with advanced ROS1-positive lung cancer or other ROS1-positive cancers. It's for those who have tried other treatments, can't join a regular trial, and have few other options available.
Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)Belgium - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaBelgium - RecruitingPHASE3
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This study is testing a medication called Pitolisant for people aged 6 and over with Prader-Willi syndrome. It aims to see if it helps with excessive sleepiness and other behaviors, compared to a dummy pill.
Prader-Willi SyndromeBelgium - Active not recruitingPHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This study tested new treatments for Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, in people who had not been treated before. It compared different drug combinations to see which worked best to slow down or stop the cancer's progress.
Chronic Lymphocytic LeukemiaBelgium - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
Metastatic Breast CancerBelgium - RecruitingPHASE2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
This study is testing a new medicine called RLY-2608 for adults and children with certain conditions where parts of their body have grown too much or developed unusually due to a specific genetic change. It aims to see if the medicine is safe and if it can help improve these conditions.
PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular MalformationsPIK3CA MutationBelgium - Active not recruitingPHASE2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
This study is testing a new medicine, Volixibat, for people with Primary Biliary Cholangitis (PBC) who experience bothersome itching. We want to see if Volixibat can reduce itching and if it affects how PBC develops. It's a Phase 2 study, meaning we're still learning about its effects.
Primary Biliary CholangitisPBCBelgium - RecruitingPHASE2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
This study looks at a new medicine called Axatilimab for children aged 2-17 with a condition called chronic Graft-versus-Host Disease (cGVHD). These children have already tried at least two other treatments. The study compares Axatilimab with existing best treatments to see which works better.
Chronic Graft-versus-host-diseaseBelgium - Active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
Breast CancerCholangiocarcinomaColorectal CancerHead and Neck NeoplasmsBelgium - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
This study is looking into a new medication called Afimkibart for adults with moderate to severe rheumatoid arthritis. It's for those who haven't found enough relief from or can't take other common treatments. The aim is to see how well it works and if it's safe.
Rheumatoid ArthritisBelgium - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerBelgium - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionBelgium - RecruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
Amyotrophic Lateral SclerosisBelgium - Not yet recruitingPHASE3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
This study is looking at a new medicine called orforglipron for young people aged 10-17 with type 2 diabetes. It compares it with an existing medicine, dulaglutide, to see how well it works and if it's safe. The study lasts about 61 weeks.
Diabetes Mellitus, Type 2Belgium - RecruitingPHASE1
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
This study is looking at how a new medicine, Afimkibart, affects how your body processes other common medicines in people with active ulcerative colitis. We want to see if it changes how your body uses them.
Active Ulcerative ColitisBelgium - RecruitingPHASE3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, called LUNAR-2, is looking at a new treatment for advanced lung cancer. It combines a device called NovoTTF-200T with standard immunotherapy (pembrolizumab) and chemotherapy to see if it helps people live longer and stops cancer from growing.
Metastatic Non-small Cell Lung CancerBelgium - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
Non-small Cell Lung CancerBelgium - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
Metastatic Colorectal CancerBelgium - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisBelgium - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
Follicular Lymphoma (FL)Belgium - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaBelgium - RecruitingPHASE3
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
This study is testing a new medicine, Givinostat, for boys aged 9-17 with Duchenne muscular dystrophy who use a wheelchair. Researchers want to see if it helps reduce muscle decline and is safe to use. Half the boys will get the medicine, and half a dummy pill for 18 months.
Duchenne Muscular DystrophyBelgium - Enrolling by invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
This study is gathering information worldwide on a rare condition called Congenital Portosystemic Shunt (CPSS). It aims to better understand how CPSS affects people, why some develop serious problems, and how best to manage it. This will help improve care for those with CPSS.
Congenital Portosystemic ShuntCPSS (Congenital Portosystemic Shunt)Belgium - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerBelgium